Aura Biosciences, Inc. (AURA) is a Healthcare stock trading at $7.75 (as of 2026-08-20), with a market capitalization of $804.23M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Aura Biosciences, Inc. is a biotechnology company focused on developing cancer therapies. It works with a virus-like drug conjugate (VDC) platform and develops the VDC candidate AU-011 for ocular oncology, including primary choroidal melanoma and additional indications such as choroidal metastases, and it is based in Cambridge, Massachusetts.
| Price | $7.75 |
| Market Cap | $804.23M |
| Price / Book | 2.55 |
| FCF Yield | -23.3% |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | Matrix Capital Management Company, LP ($46.31M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Elisabet de los Pinos |
| Employees | 106 |
| Country | US |
| IPO Date | 2021-10-29 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.